SMSbiotech
CompanyUnited States
SMSbiotech develops one asset, in phase 1 (Small Mobile Stem Cells in chronic obstructive lung disease). Mostly cell therapy; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 2
- Signals
Pipeline
1Stem cells delivered into the lung aim to regenerate lung tissue.
Phase 1, Cell therapy, chronic obstructive lung disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals2